Press Releases

AUSTIN, Texas--(BUSINESS WIRE)--

Mesa Royalty Trust (NYSE: MTR) announced the Trust income distribution for the month of August 2008. Unitholders of record on August 29, 2008 will receive distributions amounting to $1,470,213 or $0.788914432 per unit payable on October 31, 2008. The Trust received $730,111 and $91,810 from the New Mexico and Colorado portions of the San Juan Basin Properties, respectively. Royalty income from the Hugoton Properties totaled $657,268.

Effective July 1, 2008, the name of The Bank of New York Trust Company, N.A. was changed to The Bank of New York Mellon Trust Company, N.A.

Source: Mesa Royalty Trust

SAN CARLOS, Calif., Aug. 21 /PRNewswire/ -- Menlo Park Artist Tiffany Birch announces her opening reception, Lighting up with Art, scheduled Friday, September 12, 2008 from 7:00 to 9:00 pm at Niko Lighting in San Carlos, California. This reception honors the collaboration of Ms. Birch; Niko Lighting; and Linda Lenore, Feng Shui Grand Master, to showcase her work in the atmosphere of hand-crafted lighting fixtures which adorn the store.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080821/AQTH079)

"I am very pleased to have this elegant showroom as a gallery for my artwork," says Ms. Birch. "Niko Lighting provides a creative environment that reveals my paintings as individuals would see them in their personal settings."

Each of the 18 paintings was placed deliberately according to Feng Shui principles. "It is my philosophy that Feng Shui enhances and supports the flow of creative movement," says Ms. Birch. "Ms. Lenore, who is only one of three Grand Masters in the United States, applied her expertise to enhance my paintings among this elegant lighting and create a unique gallery setting."

Ms. Birch is an inspirational artist who understands how to create symbolic representations of people's souls that reflect aspects of their personality. Paintings, such as Dancing Jewel, shimmer in exuberant colors against a blue background that looks like laughter floating in air. Other works, such as Beginning, move from the vibrant solar flares of the universe into a world surrounded by the flow of love that brings a sense of peace when viewed.

Living in Northern Virginia, Ms. Birch's exploration of art led to the Art League of Olde Town Alexandria, Virginia where her passion for imagery enabled her to produce 60 paintings in 45 days. Her artwork was represented by Marin-Price Galleries in Chevy Chase, Maryland. Her move to the San Francisco Bay Area in 2002 fueled her passion for art as she worked not only with private and corporate clients but also with children, teaching them art through special programs for the Charter Learning Center of San Carlos and Lucile Packard Children's Hospital. Her recent exhibit of shimmering hues adorned the walls of Ariba Headquarters in California.

Ms. Birch's work can be viewed at Niko Lighting, 1148 San Carlos Avenue; San Carlos, CA 94070 during normal business hours and is available for sale. Many of Ms. Birch's work can be viewed on her website: http://www.tiffanybirch.com.

SOURCE T. Birch Studio

CALGARY, ALBERTA--(Marketwire - Aug. 21, 2008) - Crew Energy Inc. ("Crew") (TSX: CR) and Gentry Resources Ltd. ("Gentry") (TSX: GNY) are pleased to jointly announce that Gentry received today shareholder and court approvals for the previously announced Plan of Arrangement pursuant to which Crew will acquire all of the issued and outstanding common shares of Gentry on the basis of 0.22 of a common share of Crew for each outstanding common share of Gentry (the "Transaction"). Shareholders of Gentry voted in excess of 87% in favour of the Transaction.

Subject to the satisfaction of customary closing conditions, the Transaction is expected to become effective on August 22, 2008.

Forward Looking Statements

This press release contains forward looking statements and forward looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "estimate", "believe", "forecast" and familiar expressions are intended to identify such forward looking statements. Specifically, this press release contains forward looking statements relating to the anticipated completion of the proposed Transaction and the anticipated timing for completion of the Transaction. Crew and Gentry have provided these anticipated times in reliance on certain assumptions that they believe are reasonable at this time, including the timing and receipt of the necessary approvals and the satisfaction of the conditions to closing of the Transaction. Accordingly, readers should not place undue reliance on the forward looking statements and information contained in this press release concerning the satisfaction of such conditions, approvals or the timing thereof. The forward looking statements and information contained in this press release are made as of the date hereof and Crew and Gentry undertake no obligation to update publicly or revise any forward looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

FOR FURTHER INFORMATION PLEASE CONTACT:
        Crew Energy Inc.
        Dale O. Shwed
        President and Chief Executive Officer
        (403) 266-2088

        Crew Energy Inc.
        John G. Leach
        Vice President, Finance & Chief Financial Officer
        (403) 266-2088

        Gentry Resources Ltd.
        Hugh G. Ross
        President and Chief Executive Officer
        (403) 264-6161

        Gentry Resources Ltd.
        Ketan Panchmatia
        VP Finance and Chief Financial Officer
        (403) 264-6161

Source: Gentry Resources Ltd.

GENEVA--(BUSINESS WIRE)--

Acrongenomics, Inc. (OTCBB: AGNM) are pleased to announce that they have signed an agreement dated August 19, 2008 to restructure the relationship with Molecular Vision Limited, which terminates the May 23, 2007 Development Agreement and has resulted in Acrongenomics holding a substantial equity position in Molecular Vision. The parties have agreed to work jointly, using best endeavours, to sign documents by August 29, 2008 which set out more fully the terms of the agreement.

Molecular Vision is developing low cost, point-of-care diagnostic devices which will greatly extend the in-house tools available to the general medical practitioner. The devices are being developed to allow near patient quantitative diagnosis, currently focusing on key areas of high disease burden, including kidney function and cardiovascular disease.

Under the terms of the agreement, Acrongenomics will own more than 25% of Molecular Vision (on an undiluted basis) and becomes its largest single shareholder, in consideration of its substantial contributions to the development of Molecular Vision's technology. In addition Acrongenomics will be entitled to appoint a director to the board of Molecular Vision, subject to remaining a substantial shareholder in the company.

In further consideration of the considerable contribution made by Acrongenomics to the development of the technology and in addition to the above, both companies have agreed that Acrongenomics should be receiving a royalty revenue stream for all products that use Molecular Vision's current intellectual property estate, whether marketed directly by Molecular Vision or indirectly by any major licensee. This will create a stream of revenues for Acrongenomics

Since both companies share the view that it is to their best interest to centralize the commercialization process and keep it under the same umbrella, Acrongenomics' license to exclusive rights to Molecular Vision's technologies in certain fields are now terminated, as well as its obligations under the Development Agreement dated May 23, 2007.

Platon Tzouvalis, President of Acrongenomics said, "This is a great day for our company. This agreement with Molecular Vision is a major milestone for Acrongenomics, since it marks our substantial sharing in everything that this technology has to offer. We are proud of the development of the Molecular Vision technology to date and keen on joining forces under the same corporate roof to take it even further. This will allow Acrongenomics and Molecular Vision to focus on the goals of developing the technology and bringing great products to the market, thus increasing our shareholder value and substantially contributing to the betterment of the healthcare system in general."

About Acrongenomics Inc.

Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in Geneva, Switzerland.

About Molecular Vision:

Molecular Vision is an Imperial College spin-out company that develops low-cost diagnostic devices for use in the doctor's surgery and in the home. Its proprietary devices combine microfluidic chips with organic-semiconductor light-sources and photodetectors to provide lab-quality diagnostic tests in a miniaturised, easy-to-use, disposable format.

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements of historical facts are forward-looking statements. Forward-looking statements in this document include that we will sign more definitive agreements by August 29, 2008; that we will have a revenue stream from the royalty on Molecular Vision products; and that Molecular Vision's technology allows near patient quantitative diagnosis, and that Molecular Vision will bring great products to market; that we will increase shareholder value and contribute to the healthcare system. A number of factors may affect cause those results to differ materially from those indicated. Such factors include our limited operating history, the possibility that we are not able to agree on final documents, Molecular Vision's need for significant capital to finance internal growth as well as strategic acquisitions; its ability to attract and retain key employees and strategic partners; its and our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; the possible unacceptability of Molecular Vision's products by health care authorities and/or practitioners; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

Source: Acrongenomics, Inc.

WASHINGTON, Aug. 21 /PRNewswire-USNewswire/ -- The Republican National Committee (RNC) launched a new Web site today, ObamaRezkoShadyDeal.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080519/RNCLOGO)

The Web site will provide users with videos and the latest news pertaining to Barack Obama's lack of judgment and questionable dealings with campaign fundraiser and convicted felon Tony Rezko.

To visit the Web site, click here: http://www.gop.com/ObamaRezkoShadyDeal/

To learn more about Barack Obama, click here: http://www.meetbarackobama.com/

Paid for by the Republican National Committee. Not authorized by any candidate or candidate's committee.

SOURCE Republican National Committee